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Abstract The bronchial microbiome in severe COPD during
stability and exacerbation in patients chronically colonised by
Pseudomonas aeruginosa (PA), has not been defined. Our
objective was to determine the characteristics of the bronchial
microbiome of severe COPD patients colonised and not
colonised by P. aeruginosa and its changes during exacerba-
tion. COPD patients with severe disease and frequent exacer-
bations were categorised according to chronic colonisation by
P. aeruginosa. Sputum samples were obtained in stability and
exacerbation, cultured, and analysed by 16S rRNA gene am-
plification and pyrosequencing. Sixteen patients were includ-
ed, 5 of them showing chronic colonisation by P. aeruginosa.
Pseudomonas genus had significantly higher relative abun-
dance in stable colonised patients (p=0.019), but no signifi-
cant differences in biodiversity parameters were found
between the two groups (Shannon, 3 (2–4) vs 3 (2–3),
p=0.699; Chao1, 124 (77–159) vs 140 (115–163), p=0.364).
In PA-colonised patients bronchial microbiome changed to a
microbiome similar to non-PA-colonised patients during
exacerbations. An increase in the relative abundance
over 20 % during exacerbation was found for Streptococcus,
Pseudomonas, Moraxella, Haemophilus, Neisseria,
Achromobacter and Corynebacterium genera, which include
recognised potentially pathogenic microorganisms, in 13 pa-
tients colonised and not colonised by P. aeruginosa with
paired samples. These increases were not identified by culture
in 5 out of 13 participants (38.5 %). Stable COPD patients
with severe disease and PA-colonised showed a similar biodi-
versity to non-PA-colonised patients, with a higher relative
abundance of Pseudomonas genus in bronchial secretions.
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Exacerbation in severe COPD patients showed the same mi-
crobial pattern, independently of previous colonisation by
P. aeruginosa.
Introduction
Sputum has traditionally been used for the identification of
bronchial infection by potentially pathogenic microorganisms
(PPMs) in exacerbated chronic obstructive pulmonary disease
(COPD) patients, and positive cultures are found in a significant
proportion of patients in this clinical setting, Haemophilus
influenzae, Streptococcus pneumoniae and Moraxella
catarrhalis being the bacteria most often recovered [1, 2].
P. aeruginosa is a cause of exacerbation in severe COPD
patients [3–8], and studies that have collected sequential sam-
ples of bronchial secretions from patients with advanced dis-
ease have demonstrated that the acquisition of this PPM is in
most cases associated with the appearance of exacerbation
symptoms [9]. Advanced respiratory disease is considered a
significant risk factor for P. aeruginosa infection when exacer-
bation symptoms appear, together with previous
hospitalisations and antibiotics or steroid courses, and the use
of antibiotic therapy targeting this PPM is recommended in
current guidelines when these determinants are identified [10].
Persistence of positive cultures of bronchial secretions for
P. aeruginosa after an exacerbation occurs in a minority of
severe COPD patients, and in most cases is a transient phe-
nomenon [11]. However, long-term persistence of
P. aeruginosa as a chronic colonising strain has been reported
in up to one fifth of COPD patients with a sputum culture
positive for this PPM [9, 11, 12], and more commonly in
patients who had associated bronchiectasis [13]. COPD pa-
tients with severe disease who have had previous positive
cultures for P. aeruginosa have a worse prognosis when exac-
erbation symptoms appear [8], and the use of antibiotic ther-
apy active against P. aeruginosa in these patients is common in
current practice [12], but open to debate [14].
Currently available culture-based techniques are not suit-
able for the identification of up to 80 % of microorganisms
inhabiting mucosal surfaces [15, 16]. Bacteria that are part of
the respiratory microbiome are difficult to culture by conven-
tional methods, and false-negative results are often found in
the face of obligate anaerobes and when bacterial loads are
low [17]. The application of pyrosequencing to PCR-
amplified 16S rRNA gene has taken the study of microbial
diversity to an unprecedented level of detail [18–20]. Culture-
independent microbiological techniques have demonstrated
that the bronchial tree is not sterile during health and have
documented significant changes in the respiratorymicrobiome
in chronic lung diseases [21]. In this study, we aimed to
determine the differences in the bronchial microbiota in severe
COPD patients with chronic colonisation by P. aeruginosa
and in patients non-colonised by this PPM and the change of
this microbiota when an exacerbation appears, identifying the
microorganisms that overgrow during the episode. Bronchial
secretions were examined by amplification and pyrosequenc-
ing of the 16S rRNA gene, and patients with and without
chronic colonisation by this PPM were compared, both in
stability periods and during exacerbation.
Materials and methods
Design and population
We enrolled a cohort of stable severe COPD outpatients who
had been diagnosed according to the criteria of the Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
[22] and who had reported more than two exacerbations
per year, between January and December 2010. Patients
were examined at baseline in a stable condition from >8
weeks, and their sociodemographic data, smoking habits,
respiratory symptoms, treatments, sputum microbiological
characteristics and lung function were recorded.
Participants were followed for 6 months after this baseline
assessment, and follow-up visits were scheduled every 3
months, or when exacerbation symptoms appeared. Every
visit included the recovery of spontaneous sputum samples
that were processed for microbiological cultures and culture-
independent microbiological techniques. Detailed exclusion
criteria are provided in the online supplementary file. Acute
episodes of increased breathlessness, sputum production
and/or purulence appearing during follow-up and treatment
with antibiotics and/or oral corticosteroids by a physician
were considered exacerbations [23]. Patients with positive
cultures for P. aeruginosa in three or more consecutive
sputum cultures obtained during a period of 6 months before
enrolment in the study were considered to be chronically
colonised by this PPM [24, 25]. The present study was
reviewed and approved by the local research ethics commit-
tee in Catalonia, Spain, and written informed consent was
obtained from all subjects.
Clinical variables, sputum collection and microbiology
Sociodemographic data were recorded at recruitment. Patients
answered an epidemiological questionnaire that covered
smoking habits, respiratory symptoms, previous exacerba-
tions and treatments. Spontaneous sputum was collected from
every patient under clinical stability and during exacerbation,
before the administration of antibiotic therapy. Details on the
clinical variables and microbiological processing are provided
in the supplementary file.
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Samples and DNA extraction
Sputum samples diluted with dithiothreitol were incubated at
37 °C for 15 min and centrifuged for 10 min at 4 °C. The
pellet was resuspended in 1 ml of a lysis buffer containing
100 U/ml mutanolysin, 47,700 U/ml lysozime and 2 U/ml
lysostaphin, and was incubated for 30 min at 37 °C. DNA
was extracted using a QIAamp DNA Blood Midi kit
(Qiagen, Helden, Germany) according to the manufacturer’s
instructions and eluted in 200 μl of sterile water. DNA was
quantified in the Nanodrop ND-1000 Spectrophotometer
(NanoDrop Techologies, Wilmington, DE, USA) and stored
at –80 °C.
PCR amplification of the V1–V3 region of the 16S rRNA
gene
The hypervariable regions V1, V2 and V3 of the 16S rRNA
gene were amplified with E8 forward (AGAGTTTGAT
CMTGGCTCAG) and B530 reverse (CCGCGGCKGCTG
GCAC) primers and with 12 different barcodes. The PCRs
were carried out in a volume of 40 μl with Biomix (Bioline,
London, UK) and 10 mM of each primer, and were performed
on the Mastercycler® pro thermal cycler (Eppendorf,
Hamburg, Germany). After amplification, the products were
visualised in 2 % agarose gels. Amplified product was puri-
fied using NucleoFast® 96 PCR Clean-Up kit (Macherey-
Nagel, Düren, Germany), eluted in 28 μl of PCR-grade water
and quantified with Quant-iT PicoGreen dsDNA Assay Kit
(Invitrogen, Life Technologies, Carlsbad, CA, USA). Twelve
samples with different barcode sequences were pooled in
equimolar amounts into a single tube and pyrosequencing
was carried out using Roche 454 GS-FLX System Titanium
Chemistry.
Library analysis sequences and microbiome accession
numbers
16S rRNA raw sequences were analysed using the
mothur software package 1.27 [26] to remove sequences that
were less than 200 bp or greater than 520 bp in length and
chimeras. The Quantitative Insights into Microbial Ecology
(QIIME) pipeline [27] was used for sequence processing to
obtain taxonomic information. A taxonomic classificationwas
performed and operational taxonomic units (OTUs) present in
the samples at 97 % identity were determined.
Bacterial 16S rDNA data sets from this study are accessible
in the European Nucleotide Archive under the study accession
number PRJEB4144, available at http://www.ebi.ac.uk/ena/
data/view/PRJEB4144, with the sample accession numbers
ERS255709–739.
Statistical analysis
Statistical analyses were performed using SPSS statistical
software package version 18 (SPSS, Chicago, IL, USA), R
package (http://www.r-project.org), using the VEGAN
library to cluster and construct abundance heat maps and
LEfSe to identify differences between groups [28]. Results
for categorical variables are expressed as absolute and
relative frequencies and results for continuous variables as
means and standard deviations (SD), or as medians and
percentiles 25–75 (P25–P75) when the distribution was not
normal.
Table 1 Patients’ characteristics
No statistically significant differ-
ences between PA-colonised and
non-PA-colonised patients for any
variable
SD standard deviation; IQR inter-
quartile range; FEV1 post-BD
post-bronchodilator forced expi-
ratory volume in 1 s; BMI body
mass index; 6MWD 6-min walk-
ing distance; BODE index body
mass index, airflow obstruction,
dyspnoea, and exercise capacity
index; PPM potentially pathogen-
ic microorganism
Patients Total PA-colonised Non-PA-colonised
n 16 5 11
Age (years), mean (SD) 71 (6) 72 (7) 70.5 (6)
Male, n (%) 16 (100) 5 (100) 11 (100)
Smoking (pack-years), median (IQR) 57 (57–110) 100 (50–110) 50 (40–80)
FEV1 post-BD (% predicted), mean (SD) 36 (30–40) 41 (30–48) 34 (30–37)
Dyspnoea scale, mean (SD) 2.25 (0.6) 2.2 (0.4) 2.3 (0.6)
BMI (kg/m2), mean (SD) 28 (4) 28 (4) 28 (4)
6MWD (m), median (IQR) 240 (140–305) 300 (220–310) 230 (115–292)
BODE index, median (IQR) 5 (4.5–7.5) 5 (4–5) 6 (5–8)
Inhaled β2-adrenergics, n (%) 16 (100) 5 (100) 11 (100)
Inhaled anticholinergics, n (%) 16 (100) 5 (100) 11 (100)
Inhaled corticosteroids, n (%) 16 (100) 5 (100) 11 (100)
Positive PPM culture in stability, n (%) 12 (86) 5 (100) 7 (64)
Chronic colonisation by P. aeruginosa, n (%) 5 (31) 5 (100) 0
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Bacterial biodiversity was assessed through the Chao1
estimator [29] and Shannon [30] index, which estimate the
richness and homogeneity of the microbiome respectively.
Both indices were calculated after subsampling with QIIME
to avoid sequencing effort bias. The beta-diversity Bray–
Curtis dissimilarity index [31] was used to make principal
correspondence analysis.
Variability of the bacterial flora between consecutive sam-
ples of the same patient was expressed as a percentage of
change of relative abundance (relative abundance consecutive
sample – relative abundance baseline sample × 100). Baseline
variability for all genera was calculated by the comparison of
consecutive samples obtained during stability from the same
patient, to establish the expected variability range under
stable conditions for severe COPD patients. Variability of
the bacterial flora when exacerbation appears was equally
expressed as percentage of change of relative abundance,
using the previous baseline sample as the reference (relative
abundance exacerbation sample – relative abundance baseline
sample × 100). Statistical tests used in the study were two-
sided, and a p value of 0.05 or less was reported to be
statistically significant.
Table 2 Sputum cultures under stability and exacerbation
Stable Exacerbated
n 14 15
Positive culture for PPM, n (%) 12 (86) 10 (67)
Polymicrobial cultures, n (%) 4 (29) 3 (20)
Microorganisms
Pseudomonas aeruginosa 5 (42) 3 (30)
Haemophilus influenza 4 (33) 4 (40)
Moraxella catarrhalis 2 (17) 1 (10)
Streptococcus pneumonia 2 (17) 1 (10)
Escherichia coli 1 (8) –
Alcaligenes spp. 1 (8) 1 (10)
Staphylococcus aureus – 1 (10)
Haemophilus parainfluenzae – 1 (10)
Stenotrophomonas maltophilia – 1 (10)
Fig. 1 Relative abundance of
Pseudomonas genus a under
stability and b during
exacerbation in PA-colonised and
non-PA-colonised patients. Solid
line represents the mean and
dashed line the median
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Results
Patients’ characteristics
Sixteen severe COPD patients, 6 of them at GOLD stage III
(37.5 %) and 10 at stage IV (62.5 %), were included in the
study. All of them were former smokers with an average age
of 71 (SD 6) years (Table 1). Five patients had criteria of
chronic P. aeruginosa colonisation, and participants were clas-
sified into two groups according to colonisation by this PPM.
Microbiological data of both groups were compared and the
variability in exacerbation was assessed for PA-colonised and
non-PA-colonised patients, using the previous available re-
sults in stability as the reference.
Bronchial microbiome
Microbiological cultures were performed in sputum samples
obtained during stability (n=14) and exacerbation periods (n=
15). Cultures were positive for PPMs in 12 stability (86 %)
and 10 exacerbation samples (67 %), P. aeruginosa and
H. influenzae being the most frequent isolated PPMs in the
studied patients (Table 2). Culture-independent analyses were
also performed in all sputum samples obtained during stability
and exacerbation and the average number of sequences per
sample obtained after filtering was 4,695. Most prevalent
phyla in bronchial microbiome were Proteobacteria (50 %)
and Firmicutes (31 %), followed by Actinobacteria (8 %),
Bacteroidetes (6 %) and Fusobacteria (3 %). One hundred
twenty-eight different OTUs were obtained at genus level
(supplementary file: Figure 1), and after removing the OTUs
present in only one sample, the remaining ones were used for
further analysis.
The relative abundance of specific genera in samples from
PA-colonised and non-PA-colonised patients were compared,
during both stability and exacerbation periods, to assess the
effect of this colonisation on the remaining bronchial flora.
Statistically significant differences were only found in the
Pseudomonas genus, which had a higher relative abundance
in PA-colonised patients in both the stable and the exacerbated
state (Fig. 1, p=0.019 and p=0.003 respectively, Mann–
Whitney U test). The biodiversity of bacterial communities
in sputum samples obtained during stability measured with
Chao1 richness estimator and Shannon index value showed
no statistically significant differences between PA-colonised
and non-PA-colonised groups (Shannon index, 3 (2–4) vs 3
(2–3), p=0.669; Chao index, 124 (77–159) vs 140 (115–163),
p=0.364; Mann–Whitney U test). Similar results were obtain-
ed for the samples obtained during an exacerbation (Shannon
index, 4 (2–4) vs 4 (2.5–5), p=0.595; Chao index, 165 (93–
196) vs 163 (70–193), p=0.679, Mann–Whitney U test).
Rarefaction curves were calculated for PA-colonised and
non-PA-colonised patients using the observed species metric
(supplementary file: Figure 2) and showed that the number of
sequenced taxa was enough to estimate total population di-
versity in both groups. Differences between microbial com-
munities in both groups of patients were assessed by principal
coordinates analyses with the Bray–Curtis beta-diversity met-
ric, with samples obtained during stable (Fig. 2a) and exacer-
bation periods (Fig. 2b). Genera with the highest relative
abundance were plotted in this analysis, and two clusters were
observed in samples obtained during a stability period, corre-
sponding to PA-colonised or non-PA-colonised samples, with
Pseudomonas, Corynebacterium and Moraxella as the most
abundant genera in colonised patients. During exacerbation,
samples from PA-colonised and from non-PA-colonised pa-
tients did not cluster separately. The Bray–Curtis metric was
also used after pooling all patients for clustering together
Fig. 2 Principal coordinate analysis with Bray–Curtis dissimilarity in-
dex. a Samples from stability and b samples of exacerbation. Red dots
represent colonised patients, and blue dots non-PA-colonised patients
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patients colonised by P. aeruginosa during stability (PS) and
exacerbation (PE); and stable (S) and exacerbated (E) non-PA-
colonised COPD patients, according to genera composition
(Fig. 3). In this analysis the bacterial community obtained
during an exacerbation in PA-colonised patients showed a
closer similarity to the microbiome of non-PA-colonised se-
vere COPD participants, in both stable and exacerbated states,
than to the microbiome recovered from PA-colonised patients
during their stability periods. When most abundant genera in
the four clinical situations were represented in a heat map, a
range of genera showed low relative abundance but high
prevalence, which included Veillonella, Actinomyces,
Granulicatella, Neisseria, Prevotella, Tannerella, Gemella,
Rothia and Achromobacter, with Streptococcus as the most
abundant genus in all clinical situations (Fig. 4).Haemophilus,
Moraxella and Pseudomonas genera, which include the main
PPM in COPD, were also frequently recovered, but showed a
high variability among the four assessed clinical situations.
Pseudomonas genus was the most common in stable PA-
colonised patients, Haemophilus being the genus more often
found in non-PA-colonised patients and during exacerbation,
independently of the previous history of P. aeruginosa
colonisation.
Variability in bronchial microbiome during exacerbation
Baseline variability of the bronchial microbiome in severe
COPD was determined calculating the percentage of variation
Fig. 4 Heat map showing the
most abundant genera in the four
groups of samples. Columns
represent the groups and rows the
genera whose relative abundance
is >1 % in at least one sample.
The relative abundance of each
genus is represented by the colour
key
Fig. 3 Cluster dendrogram with Bray–Curtis dissimilarity index. Sam-
ples were combined depending on their clinical situation and clustered
with the Bray–Curtis index, which takes values between 0 and 1 (0
meaning that samples share all the genera and 1 meaning samples do
not share any). PS colonised by P. aeruginosa under stability; PE
colonised by P. aeruginosa during exacerbation; S non-colonised by
P. aeruginosa under stability; E non-colonised by P. aeruginosa during
exacerbation)
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for all examined genera in two sputum samples obtained
consecutively (>2 weeks) during stability from 2 patients
(relative abundance consecutive sample – relative abundance
baseline sample × 100), and was below 20% for all the genera
studied (n=96; Fig. 5a). Changes over this value were accord-
ingly considered abnormal for subsequent analysis. The same
approach was followed for the calculation of the variability of
every genus in the bronchial flora when exacerbation appears
in 13 patients with paired samples from stability and
exacerbation. Genera with increases over 20 % in
exacerbations included Streptococcus, Pseudomonas,
Moraxella, Haemophilus, Neisseria, Achromobacter and
Corynebacterium, all of which include recognised PPMs.
The increase observed for specific genera when exacerbation
symptoms appear paralleled a decrease of the samemagnitude
in the relative abundance for genera unrelated to this exacer-
bation, without major changes in the remaining bronchial
microbiota. Exacerbation-related variability in PA-colonised
and non-PA-colonised patients was similar, and did not show
statistically significant differences in the genera that showed
increases in their relative abundance over 20 % (p>0.05, Chi-
squared test; Fig. 5b, c).
Increases over 20 % in specific genera identified by
16SrRNA gene pyrosequencing were compared with culture
results during exacerbation in the same sample, in order to
determine the sensitivity of microbiological cultures for de-
tecting the identified changes in the bronchial microbiome. In
5 out of 13 patients (38.5 %) microbial cultures did not show
PPMs whose genera increased over 20 % from baseline at
pyrosequencing. Three of these patients had negative sputum
cultures during exacerbation and 1 patient showed a positive
culture for P. aeruginosa, while an increase over 20 % was
detected for Moraxella genus at pyrosequencing without sig-
nificant changes in Pseudomonas genus abundance. In the
fifth patient, an increase in Achromobacter genus was shown
by the culture-independent technique, while the sputum cul-
ture was positive for Stenothropomonas maltophilia and
Alcaligenes spp. In 2 exacerbated patients positive sputum
cultures showed a PPM previously recovered during stability.
These patients were considered to be colonised, and their
pyrosequencing results did not show an increase in abundance
over 20 % for any genera (Table 3).
Discussion
This study analysed the microbiome of severe COPD patients
through amplification and pyrosequencing of the 16S rRNA
gene. Assessing sputum samples obtained during stability
from patients colonised by P. aeruginosa and non-PA-
colonised patients, we observed that the microbiome of PA-
colonised COPD patients showed an expected increase in the
Pseudomonasgenus. Differences in the bronchial microbiome
between PA-colonised and non-PA-colonised patients disap-
peared during exacerbation, a clinical situation that prompted
Fig. 5 Percentage of change in the relative abundance of genera. Only
genera with a percentage of change over 20 % in at least one patient are
represented. a Percentage of variability in the genera observed in consec-
utive samples recovered in stable situation (n=2); b Percentage of vari-
ability in exacerbation in patients colonised by P. aeruginosa using the
baseline stability sample as the reference (n=5); cPercentage of variability
in exacerbation in non-PA-colonised patients (n=7). Dark blue: Neisseria;
orange: Achromobacter; purple: Streptococcus; light blue: Pseudomonas;
green: Moraxella; pink: Haemophilus; grey: Corynebacterium
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a change in the microbiome of patients chronically colonised
by this PPM to a bacterial flora equivalent to that found in
exacerbated non-PA-colonised patients. Besides, we found
that some genera increased their relative abundance during
exacerbation, including Streptococcus, Pseudomonas,
Moraxella, Haemophilus, Neisseria, Achromobacter and
Corynebacterium, all of which include recognised PPMs,
and this change was equivalent in PA-colonised and non-
PA-colonised patients. Simultaneous sputum cultures did not
identify genera increasing their abundance in one third of the
exacerbations appearing in severe COPD patients.
We found that the bronchial tree of severe COPD patients
shows a wide range of prevalent genera, in agreement with
previous reports in healthy subjects and patients with moder-
ate disease [18, 19, 32]. Thus, the bacterial diversity in the
lower airway in severe COPD individuals without signs of
infection was much higher than previously anticipated, with a
complex bacterial community that includes Streptococcus,
Haemophilus, Moraxella, Veillonella, Actinomyces,
Granulicatella, Neisseria, Prevotella, Tannerella, Gemella,
Rothia and Achromobacter as the main recovered genera.
Pseudomonaswas the most common genus in stable patients
who have shown previous colonisation by P. aeruginosa, and
Haemophilus is the genus more often found in non-PA-
colonised severe patients.
In spite of the chronic presence of P. aeruginosa in the
bronchial tree of a subgroup of severe COPD patients, we
found no statistically significant differences in Chao1 and
Shannon biodiversity parameters between PA-colonised and
non-PA-colonised patients, suggesting that the presence of
P. aeruginosa in the respiratory tract of these patients does
not modify the diversity of the bronchial microbiome. The
conservation of a diverse microbiota is related to epithelial
integrity, immunoregulation and colonisation resistance [19,
33–35] and shifts in the microbial community composition
may compromise respiratory health and contribute to disease
progression. Recent studies based on culture-independent se-
quencing technologies have reported well-defined
microbiome changes in the mucosa of diverse chronic dis-
eases, such as cystic fibrosis and inflammatory bowel dis-
eases, among others [36]. The lack of differences in the
bronchial microbiome observed in PA-colonised and non-
PA-colonised patients in our study suggests that the bronchial
colonisation by this PPM is not associatedwith the appearance
of significant alterations in the bronchial flora in severe COPD
patients.
We found that the bacterial community obtained during
exacerbation in patients colonised by P. aeruginosa changes
to a flora showing a close similarity with the microbiome
found in non-PA-colonised severe COPD patients during ex-
acerbation, suggesting that acute episodes in PA-colonised
patients might be attributable to common PPMs instead of
the colonising PPM. In severe COPD, P. aeruginosa may be
recovered from sputum cultures obtained during stability pe-
riods [3–8]. Patients with persistent colonisation by
P. aeruginosa have a worse prognosis than non-colonised
patients when exacerbation symptoms appear [8], and require
prompt treatment. Accordingly, antibiotic treatments targeting
P. aeruginosa are currently recommended for severe patients
with frequent episodes of exacerbation with this clinical pro-
file [10]. In adults with COPD this approach is justified by the
features that this disease shares with cystic fibrosis, in which
Table 3 Changes in the
microbiome during exacerbation
detected by traditional cultures
and 16S pyrosequencing. Only
the increases above 20 % are de-








1 P. aeruginosa ↑ Moraxella PPM not identified by culture
2 H. influenzae ↑Haemophilus No additional information
3 P. aeruginosa Only changed <20 % Colonising P. aeruginosa
4 H. influenzae ↑Haemophilus No additional information
5 Negative ↑Pseudomonas PPM not identified by culture
Non-PA-colonised patients
1 H. parainfluenzae ↑Haemophilus No additional information
2 H. influenzae ↑Moraxella No additional information
M. catarrhalis
3 H. influenzae ↑Haemophilus No additional information
4 S. pneumoniae Only changed <20 % Colonising S. pneumoniae
5 Negative ↑Moraxella PPM not identified by culture
6 S. pneumoniae ↑Streptococcus No additional information
7 S. maltophilia ↑Achromobacter PPM not identified by culture
Alcaligenes spp.
8 Negative ↑Streptococcus PPM not identified by culture
1108 Eur J Clin Microbiol Infect Dis (2014) 33:1101–1111
P. aeruginosa causes chronic colonisation and is associated
with significant morbidity and mortality [37–39].
Extrapolating observations from cystic fibrosis to COPDmust
be done with caution, however, because the carriage patterns
of P. aeruginosa differ substantially in the two diseases [11,
40, 41]. Our findings suggest that exacerbation symptoms in
PA-colonised patients are mainly related to PPMs that are a
frequent cause of exacerbation in non-PA-colonised COPD
patients rather than P. aeruginosa infection.
The variability in the abundance of genera in bronchial
secretions observed during stability and exacerbation periods
was assessed in our study, and stable severe COPD patients
showed variabilities below 20 % for all genera in the absence
of exacerbation symptoms. When exacerbation appears, this
value increases well above the stability reference level for
genera such as Haemophilus, Moraxella and Streptococcus,
all of which include pathogenic species. These findings con-
firm that most cases of infectious exacerbation in severe COPD
patients are due to PPMs, which are a common cause of acute
symptoms in COPD, without significant differences between
PA-colonised and non-PA-colonised patients. This finding
suggests that antibiotic treatments prescribed for exacerbations
in PA-colonised patients need to target common PPMs instead
of the colonising PPM in the first instance. Interestingly, the
increases in relative abundance observed in specific genera
during exacerbation periods in the present study paralleled
clear decreases of a similar magnitude in other genera that also
included PPMs, without significant changes in the baseline
flora found in the bronchial tree, again with a similar pattern
in PA-colonised and non-PA-colonised patients.
The exacerbation-related changes identified in the bronchial
microbiome during exacerbation were not identified by simul-
taneous microbiological cultures in one third of the patients in
our study. Although traditional microbiological culture is the
gold standard technique for the identification of bronchial
colonisation [42], it has some limitations. A significant number
of microorganisms do not grow in selective cultures, and fast-
growing bacteria can mask other clinically important bacteria
in the sample [43]. PCR amplification of 16S rRNA gene
identifies the real composition of the lung microbiome [42]
and can help us to understand the association between the
microbiome changes and the acute stages of the disease.
Limitations of the study are the sample size, the use of
sputum samples for the assessment of bronchial secretions and
the absence of testing for viral infection. Enrolled patients
were representative of the hospital-managed population with
severe COPD, and did not suffer from severe comorbidities.
Sputum was used to examine the bronchial microbiome be-
cause these samples can be obtained easily and non-invasively
and the guidelines for the procedure include quality criteria.
Although the sputum may be contaminated by bacterial flora
of the oropharynx and the oral cavity, the microbiome com-
position that we have found in severe COPD patients is quite
similar to that of previous reports in healthy controls and
COPD patients based on the use of bronchial brushing and
bronchoalveolar lavage for the sampling of bronchial secre-
tions [18, 19]. We assumed, accordingly, that sputum is a
representative sample for the study of the microbiome of
bronchial secretions in severe COPD patients, with the addi-
tional advantage that the results obtained can be easily corre-
lated with sputum culture. Viral infection in COPD patients can
modify the bronchial microbiome [44] and changes in the
microbiome detected during exacerbation may be partly influ-
enced by the coexistence of infective virus in the bronchial tree.
Conclusions
Our data confirm that a rich bronchial microbiome is found in
bronchial secretions from stable COPD patients with severe
disease, which includes genera with well-known PPMs that
are unusual in the normal population. In severe patients
colonised by P. aeruginosa the bacterial community showed
differences with regard to non-colonised patients in their sta-
bility periods, but at times of exacerbation their microbial
profile changed to a flora that included PPMs and was equiv-
alent to the bronchial microbiome found in non-colonised
patients during exacerbation. These findings argue against
the need for differentiated antibiotic approaches to exacerba-
tion in severe COPD patients colonised by P. aeruginosa, a
suggestion that must be confirmed in larger cohorts of patients.
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